These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17565627)

  • 1. Management strategies for Barrett's esophagus.
    Hillman L
    J Gastroenterol Hepatol; 2007 Jun; 22(6):771-2. PubMed ID: 17565627
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy.
    Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
    J Gastroenterol Hepatol; 2007 Jun; 22(6):901-7. PubMed ID: 17565646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of Barrett's esophagus: can it prevent cancer?
    Sampliner RE
    Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing dysplasia in Barrett's esophagus: are proton pump inhibitors the answer?
    Mardini HE
    Am J Gastroenterol; 2005 Apr; 100(4):978-9. PubMed ID: 15784046
    [No Abstract]   [Full Text] [Related]  

  • 6. Barrett's esophagus-emerging concepts and controversies.
    Schuchert MJ; Luketich JD
    J Surg Oncol; 2007 Mar; 95(3):185-9. PubMed ID: 17323330
    [No Abstract]   [Full Text] [Related]  

  • 7. [Medical treatment of Barrett's esophagus].
    Kinoshita Y; Yuki T
    Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic surveillance of Barrett's esophagus: another viewpoint.
    Richter JE
    Am J Gastroenterol; 1993 May; 88(5):630-2. PubMed ID: 8480722
    [No Abstract]   [Full Text] [Related]  

  • 9. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
    Cooper BT; Chapman W; Neumann CS; Gearty JC
    Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression?
    Fennerty MB
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S30-7. PubMed ID: 12478242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barrett's-related esophageal adenocarcinoma: is chemoprevention a potential option?
    Fennerty MB; Triadafilopoulos G
    Am J Gastroenterol; 2001 Aug; 96(8):2302-5. PubMed ID: 11513166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
    Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Initial measures in reflux manifestations. Endoscopy or therapy attempt with proton pump inhibitors].
    Jaspersen D
    MMW Fortschr Med; 2002 Jun; 144(23):32-3. PubMed ID: 12119900
    [No Abstract]   [Full Text] [Related]  

  • 14. Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Mulholland HG; Cantwell MM; Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; McGuigan J; Reynolds JV; Comber H; Murray LJ
    Cancer Causes Control; 2009 Apr; 20(3):279-88. PubMed ID: 18839322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus.
    de Jonge PJ; Steyerberg EW; Kuipers EJ; Honkoop P; Wolters LM; Kerkhof M; van Dekken H; Siersema PD
    Am J Gastroenterol; 2006 Jul; 101(7):1421-9. PubMed ID: 16863542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is symptom control the correct end point for proton pump inhibitor treatment in Barrett's oesophagus?
    Sarela AI; Verbeke CS; Pring C; Guillou PJ
    Gut; 2004 Sep; 53(9):1387-8. PubMed ID: 15306606
    [No Abstract]   [Full Text] [Related]  

  • 17. GERD and Barrett's esophagus: diagnostic and management strategies in the geriatric population.
    Morganstern B; Anandasabapathy S
    Geriatrics; 2009 Jul; 64(7):9-12. PubMed ID: 19586085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alarming increase of esophageal cancer. Is antireflux surgery an efficient prevention?].
    Lundell L
    Lakartidningen; 2000 Dec; 97(51-52):6016-20. PubMed ID: 11195438
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of Barrett's esophagus in systemic sclerosis.
    Wipff J; Allanore Y; Soussi F; Terris B; Abitbol V; Raymond J; Chaussade S; Kahan A
    Arthritis Rheum; 2005 Sep; 52(9):2882-8. PubMed ID: 16142744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barrett's Esophagus, fundoplication, and cancer.
    Watson DI; Mayne GC; Hussey DJ
    World J Surg; 2007 Mar; 31(3):447-9. PubMed ID: 17334863
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.